Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 8

MARIPOSA Study Insights

July 16, 2024

Mark A. Socinski, MD, Helena A. Yu, MD, Zosia Piotrowska, MD, MHS , Julia Rotow, MD, Benjamin Levy, MD

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for NSCLC with Non-Actionable Mutations

EP. 2: Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP. 3: Exploring the TROPION-Lung04 Study

EP. 4: Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP. 5: Navigating Between ADCs in NSCLC

EP. 6: Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP. 7: Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

Now Viewing

EP. 8: MARIPOSA Study Insights

EP. 9: Optimizing Therapy Selection in EGFR Mutant NSCLC

EP. 10: ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP. 11: Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP. 12: Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP. 13: Targeting of HER3: Insights from HERTHENA-Lung01

EP. 14: Challenges and Learnings from EVOKE-01

EP. 15: Key ADC Studies at ASCO 2024

EP. 16: Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP. 17: Patient Selection and Sequencing of NSCLC ADCs

Please comment on the rationale for the use of amivantamab and lazertinib in 1L EGFR-mutant NSCLC and discuss recently presented efficacy and safety data from MARIPOSA. Cho, et al. ESMO 2023. Abstract LBA14